Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

FDA Recommends Roche's HPV Test as Primary Screening Tool

Published: Thursday, March 13, 2014
Last Updated: Thursday, March 13, 2014
Bookmark and Share
Test will assess risk of cervical cancer of women 25 years and older.

The FDA Microbiology Devices Panel of the Medical Devices Advisory Committee recommended unanimously that the benefits of the cobas HPV (Human Papillomavirus) Test as a first line, primary screening tool in women 25 years and older to assess their risk of cervical cancer based on the presence of clinically relevant high-risk HPV DNA outweigh the risks. The panel also voted unanimously that the cobas HPV Test is safe and effective for the proposed indication for use. If approved, the cobas HPV Test would become the first and only HPV test indicated as the first-line primary screen of cervical cancer in the United States.

“Every year, 12,000 women are diagnosed in the U.S. with cervical cancer. This is especially tragic because cervical cancer is a largely preventable disease, and it is well established that HPV is the cause of almost all cervical cancers worldwide. Women need better access to screening tools that include primary HPV screening in order to reduce their risk of developing cervical cancer,” said Dr. Thomas C. Wright, Jr., Professor Emeritus of Pathology and Cell Biology, Columbia University Medical Center, NY. “I am pleased that the FDA panel recognized the importance of validated, scientific evidence documenting the use of primary HPV screening to detect women at risk of invasive cervical cancer and allow us to prevent cervical cancer from developing.”

HPV causes more than 99 percent of cervical cancers and HPV genotypes 16 and 18 cause 70 percent of these cases worldwide. For decades, women have relied on cytology to detect evidence of disease. The ATHENA study, which included more than 47,000 women, showed that a significant number of women would benefit by using the cobas HPV Test as primary screening for cervical cancer. In fact, ATHENA demonstrated that nearly 1 in 7 women with normal Pap cytology who were HPV 16 positive actually had high-grade cervical disease that was missed by cytology.

“Through technological and scientific advancement, we now have a better screening tool for cervical cancer. Women around the world deserve the best tool to know their risk and reduce their chances of developing cervical cancer,” said Roland Diggelmann, COO Division Roche Diagnostics. “We look forward to working with the FDA and medical community to support the growing understanding and awareness of the role that HPV plays in cervical disease, and the importance of the cobas HPV Test, which provides the necessary medical benefit to become the first line test in a cervical cancer screening strategy. ”

The Committee's recommendation will be considered by the FDA in its review of the primary screening indication for the cobas HPV Test. The FDA is not bound by the Committee's guidance, but takes its advice into consideration when reviewing medical devices.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Roche Receives FDA Approval for Viral Load Tests and Cobas 6800/8800 Systems
Roche has received FDA approval for the cobas® HBV and cobas® HCV viral load tests, the first assays approved by the FDA for use on the cobas® 6800 and cobas® 8800 Systems.
Sunday, October 18, 2015
Roche Launches the cobas EGFR Mutation Test v2
New test is the first to be validated for use of either sample type in a single test.
Wednesday, October 14, 2015
Roche Receives FDA Clearance for Strep A Test
The cobas Strep A test is the first molecular point of care test to provide a result in 15 minutes for this common infection.
Friday, November 14, 2014
Roche Acquires IQuum
Acquisition will allow Roche to quickly enter the point of care segment of molecular diagnostics.
Monday, April 07, 2014
Roche Signs Licensing Agreement with Sysmex Inostics
Under the terms of the agreement, Roche grants Sysmex a worldwide, non-exclusive, royalty-bearing license.
Friday, February 21, 2014
Roche’s MycoTOOL Receives Acceptance from Canadian Authorities
PCR test reduces time for mycoplasma detection from one month to one day.
Friday, June 14, 2013
Roche and Life Technologies Corporation Sign New PCR IVD Licenses
Companies announced that they have entered into two license agreements to allow LTC to expand its PCR offerings for diagnostics applications.
Thursday, February 23, 2012
Hamilton Introduces Automated DNA Sample Enrichment Solution
System uses Roche 454 REM e liquid handling system to replace hours of manual work.
Tuesday, January 31, 2012
Roche’s Novel Tests for the Management of Hepatitis C Virus Infection Receive CE Mark
The tests detect HCV RNA, which is a crucial marker in the management of hepatitis C infection.
Tuesday, January 17, 2012
Roche and Labcyte Integrate Echo and LightCycler Systems to Increase Performance of qPCR-based RNA/DNA Analyses
Companies cooperate around high-speed, miniaturized quantitative PCR (qPCR) to monitor the expression of tens to thousands of genes for therapeutic research.
Wednesday, December 07, 2011
Roche Signs Exclusive Agreement with IT-IS Life Sciences
Agreement to distribution the new LightCycler® Nano Instrument, which will complete the company´s portfolio for the low throughput real-time PCR systems market.
Monday, May 30, 2011
Roche and Lonza Enter into Distribution Agreement
Roche and Lonza have announced that they have entered into a co-exclusive distribution agreement for the commercialization of Roche’s MycoTOOL mycoplasma PCR assays.
Wednesday, April 13, 2011
Roche and Lonza Enter into MycoTOOL Distribution Agreement for Rapid Mycoplasma Testing Solutions
MycoTOOL test is the first commercial NAT-based detection system used for mycoplasma biosafety testing of approved biological products.
Wednesday, April 13, 2011
Roche Obtains Co-Exclusive License to Develop PCR Assays Detecting Mutations in the PI3K Oncogene
The assay will complement Roche's menu in development of assays for validated biomarkers, including the B-RAF V600E mutation.
Wednesday, July 14, 2010
Ghent University will Use Roche's LightCycler® 1536 Instrument in the Field of HT PCR for Cancer Research
Roche and Ghent University enter agreement for the use of Roche's LightCycler® 1536 Instrument in various cancer research projects in Ghent.
Thursday, April 22, 2010
Scientific News
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Best Test to Diagnose Strangles in Horses Identified
New research by Dr. Ashley Boyle of New Bolton Center’s Equine Field Service team shows that the best method for diagnosing Strangles in horses is to take samples from a horse’s guttural pouch and analyze them using a loop-mediated amplification (LAMP) polymerase chain reaction (PCR) test.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
Detecting When Hormone Treatment for Breast Cancer Stops Working
Scientists have developed a highly sensitive blood test that can spot when breast cancers become resistant to standard hormone treatment, and have demonstrated that this test could guide further treatment.
Packaging and Unpacking of the Genome
New research improves understanding of the importance of histone replacement.
New Way to Find DNA Damage
University of Utah chemists devised a new way to detect chemical damage to DNA that sometimes leads to genetic mutations responsible for many diseases, including various cancers and neurological disorders.
How Different Treatments for Crohn's Effect the Microbiome
Different treatments for Crohn's disease in children affects their gut microbes in distinct ways, which has implications for future development of microbial-targeted therapies for these patients, according to a study led by researchers from the Perelman School of Medicine at the University of Pennsylvania.
Charting the 'Genomic Biography' of Leukemia
A new study by scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard offers a glimpse of the wealth of information that can be gleaned by combing the genome of a large collection of leukemia tissue samples.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos